Remegen Co. Ltd. Class ASSE: 688331

Announcement on Voluntary Disclosure of the Conditional Marketing Application for Telitacicept for the Treatment of IgA Nephropathy

· Issued by Remegen Co. Ltd. Class A via Shanghai Stock Exchange
Announcement on Voluntary Disclosure of the Conditional Marketing Application for Telitacicept for the Treatment of IgA Nephropathy

The abstract is for reference only. Please refer to the full text of the announcement on the very day.

Link of Full Text for Reference: View Attachment

Earlier from Remegen Co. Ltd. Class A

All Remegen Co. Ltd. Class A news releases